Soleus leads $35m series-C extension for Inivata

New investors including Janus Henderson Investors and Farallon Capital also participated alongside existing investor IP Group.

The funds will primarily be used to accelerate the clinical development and continued rollout of RaDaR, the company's personalised assay for the detection and monitoring of minimal residual disease (MRD) and recurrence.

Previous funding
Imperial Innovations, Johnson & Johnson Innovation (then known as Johnson & Johnson Development Corporation) and Cambridge Innovation Capital participated in a £4m funding round for the company in 2014.

In 2016, Woodford Investment Management, Johnson & Johnson Innovation, Imperial Innovations and Cambridge Innovation participated in a £31.5m series-A in 2016.

The company raised $52.6m in a 2019 series-B, with participation from existing investors Woodford Investment Management, Johnson & Johnson Innovation and Cambridge Innovation, as well as from new investors RT Ventures and IP Group.

Listed company NeoGenomics invested $25m in the company in 2020.

Company
Cambridge-based Inivata was founded in 2014 and performs research and development in clinical cancer genomics using circulating DNA analysis to improve testing and treatment for oncologists and their patients. It generated turnover of £304,680 and a loss of £20m in 2019.

People
Inivata – Clive Morris (CEO).
Soleus Capital – Guy Levy (founder).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• UK / Ireland
• Healthcare
• Venture
• United Kingdom
• healthcare